泡沫之夏

中国新药组合，让这类癌症生存期几乎翻倍_我的网站

一 |     一                    今天继续介绍刚在欧洲肿瘤内科学会（ESMO）年会上公布，并同步发表在《新英格兰医学杂志》上的优秀研究。    

    Workers harvest Ottelia acuminata at a planting base at Yong'an Village of Eryuan County in Dali Bai Autonomous Prefecture, southwest China's Yunnan Province, on Oct. 18, 2024.(Photo by Luo Xincai/Xinhua)Under the summer sun, Erhai Lake in southwest China's Yunnan Province glistens thanks to its clear blue water dotted with floating white blossoms. Tourists stroll and cycle around the spot, where limpid waters, lush mountains and blooming flowers combine in weaving a picturesque scene.
The delicate blossom seen floating there is Ottelia acuminata, an aquatic plant endemic to China, which is known to have extremely strict water quality requirements. It demands high water transparency, cleanliness and calcium content, and survives only in unpolluted waters, serving as a reliable natural indicator of aquatic ecological health.
Its large-scale revival vividly testifies to Erhai Lake's remarkable ecological restoration achievements.
China's Ecological and Environmental Code, enacted on Saturday, stipulates nationwide protection and restoration of river and lake ecosystems, providing solid legal support for systematic water ecological governance across the country.
As China advances its Beautiful China initiative, this code is expected to strengthen rule-of-law guarantees for ecological protection and provide fresh impetus for the country's green and low-carbon transition.
In the early 1990s, agricultural pollution worsened Erhai Lake's water quality, causing frequent blue-green algae outbreaks. A severe algae bloom hit the lake in 1996, leaving the water turbid and smelly. As the environment degraded, Ottelia acuminata nearly disappeared from the lake.
Thanks to years of targeted ecological protection and restoration efforts, the lake's water quality has improved steadily, maintaining an excellent Grade II standard from January to June 2026, and creating favorable conditions for the return of Ottelia acuminata.
Official data show that the plant's coverage on Erhai Lake has surged from 90,000 square meters in 2021 to 950,000 square meters in 2026, marking a remarkable ecological recovery.
The improved water environment has also brought tangible economic benefits, turning the lake's ecological advantages into a sustainable industry. From lake ecology to farm cultivation and consumer products, Ottelia acuminata's dual ecological and economic value has been fully realized.
In 2018, environmental worker Zhong Lan noticed the edible plant's great potential for water purification and industrial development. With support from local authorities and Shanghai Jiao Tong University in eastern China, she started a company and built a professional research base in 2024, developing standardized planting techniques that enable high-yield, repeated harvests and offering jobs for local villagers.
Villager Li Xinyuan, who quit Ottelia acuminata cultivation years ago due to low profits, resumed planting in 2023 and earns a stable monthly salary of 4,500 yuan (about 663 U.S. dollars) at the base.
His fellow villager Du Hongquan earned over 100,000 yuan last year from growing the plant and has more than doubled his planting area this year. "The base takes full charge of sales, so we can plant without any worries," Du said.
Eryuan County, the source of Erhai Lake, now has more than 200 hectares of Ottelia acuminata plantation area, creating numerous jobs yearly. The plant has been developed into a diverse range of products like tea, plant-based coffee and cookies.
"I used to think it was exclusive to Yunnan, but I can try it elsewhere too," said a tourist surnamed Ai after tasting the plant at a hotpot restaurant in Hangzhou, east China's Zhejiang Province.
The beautiful lakeside scenery at Erhai has also boosted local tourism. In 2025, Dali received over 120 million tourist visits, attracting visitors to enjoy lake views and experience local Bai ethnic culture, with 407,000 long-term visitors.
Last month, the State Council issued a plan for building a Beautiful China during the 15th Five-Year Plan period (2026-2030), setting out the overall requirements, targets, key tasks and major projects for comprehensively advancing this initiative.
According to the plan, China will achieve overall improvement in ecological and environmental quality and make significant progress toward building a Beautiful China by 2030, with green production and lifestyles largely established and the carbon peaking target reached on schedule.
。今天这个很特别，因为论文作者全是中国人。这次研究从药物开发到临床研究，都来自中国。                             在所有泌尿系统肿瘤中，膀胱癌是最常见的一种，中国每年新发病例近10万人。膀胱癌最常出现在中老年男性身上，重要原因就是吸烟。吸烟是膀胱癌最重要的单一危险因素，吸烟者的风险是不吸烟者的3到4倍。                   膀胱癌如果发现得早，生存率挺高的，但一旦进展为晚期，情况就完全不同了。晚期膀胱癌很容易耐药和复发，是“最难啃的骨头”之一。

二 |                    过去几十年，化疗一直是这类患者的主力治疗手段，但效果有限，中位生存期只有一年多，副作用还挺大。最近，有两类新药给患者带来了新希望，一个是免疫药物，一个是抗体偶联药物（英文缩写是ADC）。                   膀胱癌是对免疫治疗整体响应比较好的一类肿瘤，多款PD-1／PD-L1 类免疫药物都在膀胱癌中获批，包括大家熟悉的K药，O药等。

三 |                    抗体偶联药物也是最近很火的一类药物，它的本质是“导弹模式”：用靶向肿瘤的抗体来把化疗药带到肿瘤细胞附近，从而进行更精准的杀伤。膀胱癌中最早获批的一个抗体偶联药物是维恩妥尤单抗，它的靶点是膀胱癌表面的Nectin-4蛋白。                   这两类新药都已经获批，但单独都有自己的局限，比如免疫治疗单用有效率偏低，而抗体偶联药物副作用偏大，疗效持续性不够长。于是有科学家想到，能不能强强联合，一面用导弹轰炸肿瘤，一面激活免疫，或许1+1能大于2？                    说干就干，这次的研究就是这样。科学家把两个已经在中国获批，用于膀胱癌治疗的国产新药联合了起来，一个是PD1免疫药物，特瑞普利单抗，另一个是针对HER2的抗体偶联药物，维迪西妥单抗（有人可能熟悉它以前的代号RC48）。                   有人可能会问，HER2不是乳腺癌靶点么，怎么膀胱癌也能用？                    确实，HER2最早是在乳腺癌中成功的靶点。曲妥珠单抗等HER2靶向药的出现，让无数HER2阳性乳腺癌患者获得了长期生存。

四 | 但其实HER2在别的肿瘤上也有表达，包括膀胱癌。                   事实上，超过一半的膀胱癌都有HER2蛋白表达，只不过以往曲妥珠单抗在这里效果不好，所以没有作为一个靶点来看。

五 | 但随着维迪西妥单抗这样新型抗体偶联药物出现，改变了这个结果。2021年，它已经在中国获批用于HER2阳性膀胱癌的二线治疗。                   这次临床研究，目标是改变一线治疗标准。研究纳入了484名HER2表达阳性的晚期尿路上皮癌患者（主要是膀胱癌），然后随机分为两组：一组接受维迪西妥单抗+特瑞普利单抗，另一组接受传统化疗。

六 |                    结果很清楚，新药各个指标都碾压化疗。                             患者客观缓解率高达76.1%，也就是说，每四个接受新方案的患者中，就有三个人肿瘤明显缩小。中位无进展生存期从6.5个月延长到13.1个月，中位总生存期从16.9个月延长到31.5个月，都几乎翻倍了。

七 |                    生存曲线上，两条线分得越开，效果就越好。                   当然，任何疗法都有副作用。新组合疗法安全性比化疗整体好一点，但有一些特别的副作用，比如周围神经病变（手脚麻木）和间质性肺病，它们虽然发生率低，但如果严重会很危险，甚至致命，所以如果后续上市后使用，需要大家配合医生严密监控，尽量早期干预。                   二                    值得一提的是，这已经不是第一个在膀胱癌取得成功的免疫+抗体偶联药物组合了。                   在此之前，两个进口药，维恩妥尤单抗和帕博利珠单抗（K药），也是在《新英格兰医学杂志》，发表了代号为EV-302的三期随机对照研究结果，同样是完爆化疗：患者中位生存时间从16.1个月，延长到了31.5个月，几乎翻了一倍，患者死亡风险降低了53%。                             因为优异的数据，今年1月，中国药监局已经批准了这个联合疗法，用于局部晚期或转移的尿路上皮癌患者的一线治疗。

八 |                    虽然不同研究的数据不能直接比较，但整体看起来，这次国产药物组合的结果也处于同一水平上，获批应该只是时间问题。                   三                    最近几年，中国国产药物研发水平突飞猛进。

九 | 虽然从0到1的原创还比较少，但整体水平已经和十年前不可同日而语。这次“纯国产”的研究能发表在最顶尖的临床医学杂志上，就体现了对我国药物研发和临床实验能力整体的高度认可。

十 |                    一旦中国人做得好，就会让这个行业变得更卷，创新药也不例外。瑞普利单抗和维迪西妥单抗作为本土开发的新药，如果获批，肯定会让膀胱癌治疗性价比变得更高，对国内患者无疑是好消息。

十一 |                    膀胱癌患者一线选择已经有多个选择，包括维恩妥尤单抗+帕博利珠单抗，纳武利尤单抗+化疗，现在又加上了维迪西妥单抗+瑞普利单抗。随着新药出现，我相信以后一线纯用化疗的膀胱癌患者将会越来越少。

十二 |                    至于这些组合疗法怎么选，大概率会是基于生物标记物，比如HER2、Nectin-4、PD-L1蛋白的表达。越来越多膀胱癌患者的肿瘤会被拿去检测这些蛋白的水平，然后根据这些标记物是否表达，以及表达的多少，我们可以选择成功概率最高的一个。                   当然，现在还远没有到终点，科学的脚步不会停止。还有很多研究正在进行。                   比如耐药机制和后续选择。中位总生存超过30个月令人鼓舞，但其中多少人疗效能持续？甚至临床治愈？耐药机制如何？                    再比如，是否可以把这个组合用于更早的患者，用于手术前新辅助治疗或手术后辅助治疗？                    通过精准的靶向识别和免疫激活，新药已经给晚期膀胱癌患者点燃了新的希望。期待更多突破能够迅速进入临床实践，真正改变患者的命运。                   致敬科学，致敬生命！                    *本文旨在科普癌症新药背后的科学，不是药物宣传资料，更不是治疗方案推荐。如需获得疾病治疗方案指导，请前往正规医院就诊。                   参考文献          1. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med 2025          2. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024; 390: 875-88.                    本文来自微信公众号：菠萝因子，作者：80后菠萝博士。

Current article:http://km2.shaihanhuangwoshang.cyou/xqj1f1/20260826/80748.html

Published on:07:36:14